Tonix Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
$7.9M
Website

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-04-22
Last Posted Date
2017-04-11
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
165
Registration Number
NCT02423408
Locations
🇺🇸

Rapid Medical Research, Inc., Cleveland, Ohio, United States

🇺🇸

Avail Clinical Research LLC., DeLand, Florida, United States

🇺🇸

Duane G. Wombolt, MD, Norfolk, Virginia, United States

and more 7 locations

Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-04-21
Last Posted Date
2017-10-31
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
159
Registration Number
NCT02421679
Locations
🇺🇸

CITRIALS, Riverside, California, United States

🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

🇺🇸

Cns, Inc., Torrance, California, United States

and more 19 locations

Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers

First Posted Date
2014-11-14
Last Posted Date
2016-05-17
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
27
Registration Number
NCT02290379

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-10-29
Last Posted Date
2024-06-20
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
245
Registration Number
NCT02277704
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

🇺🇸

Altea Research, Las Vegas, Nevada, United States

🇺🇸

Cincinnati, Cincinnati, Ohio, United States

and more 20 locations

12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-12-19
Last Posted Date
2017-07-07
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
158
Registration Number
NCT02015234
Locations
🇺🇸

71 Thomas Johnson Drive, Frederick, Maryland, United States

🇺🇸

370 Faunce Corner Road, North Dartmouth, Massachusetts, United States

🇺🇸

Jackson, Jackson, Mississippi, United States

and more 10 locations

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-07-19
Last Posted Date
2016-12-23
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
205
Registration Number
NCT01903265
Locations
🇺🇸

Clinical Pharmacology Study Group, Worcester, Massachusetts, United States

🇺🇸

CRC of Jackson, LLC, Jackson, Mississippi, United States

🇺🇸

1275 Olentangy River Road, Columbus, Ohio, United States

and more 14 locations

Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults

First Posted Date
2012-09-21
Last Posted Date
2014-09-26
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT01689259
Locations
🇨🇦

PharmaNet, Inc., Quebec City, Quebec, Canada

Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults

First Posted Date
2012-07-06
Last Posted Date
2014-09-26
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT01634412
Locations
🇨🇦

PharmaNet, Inc., Quebec City, Quebec, Canada

A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-12-13
Last Posted Date
2019-09-11
Lead Sponsor
Tonix Pharmaceuticals, Inc.
Target Recruit Count
30
Registration Number
NCT01490788
Locations
🇨🇦

PharmaNet, Inc., Québec City, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath